Publications by authors named "Carole Dhelens"
Article Synopsis
- Toxic shock syndrome (TSS) is a serious but rare illness that can lead to significant health problems, especially in children, and the study aimed to test the effectiveness and safety of intravenous immunoglobulin (IG) therapy compared to a control treatment in pediatric patients.
- The study involved a randomized clinical trial with 28 participants aged 1 month to 18 years, assessing the feasibility of the trial based on inclusion rates, protocol compliance, and data completeness over a follow-up period of one year.
- The results indicated that while the trial was feasible with a high inclusion rate and low missing data, there was no significant difference in clinical outcomes between the IG and control groups, although more adverse events were noted in the control group.
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
J Intern Med
December 2023
Article Synopsis
- Bevacizumab, a monoclonal antibody, is used to treat hereditary hemorrhagic telangiectasia (HHT), but this is the first randomized trial investigating its effectiveness.
- In a double-blind study involving 24 patients, those treated with bevacizumab showed a greater decrease in blood transfusions compared to the placebo group, with significant improvements in hemoglobin levels over six months.
- Despite some positive results, the trial was underpowered, meaning more research is needed to confirm that bevacizumab helps reduce the need for blood transfusions in HHT patients, especially in those exposed to higher doses.
Background: Impulse control disorders (ICDs) are frequently encountered in Parkinson's disease (PD).
Objectives: We aimed to assess whether clonidine, an α2-adrenergic receptor agonist, would improve ICDs.
Methods: We conducted a multicentre trial in five movement disorder departments.
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Neurol
September 2022
Background: The incidence of early seizures (occurring within 7 days of stroke onset) after intracerebral haemorrhage reaches 30% when subclinical seizures are diagnosed by continuous EEG. Early seizures might be associated with haematoma expansion and worse neurological outcomes. Current guidelines do not recommend prophylactic antiseizure treatment in this setting.
View Article and Find Full Text PDFBackground: Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis possibly leading to chronic kidney disease (CKD) and bone complications in adults. Orphan diseases with different underlying primary pathophysiology share inappropriately increased 1,25(OH)D levels and hypercalciuria, e.g.
View Article and Find Full Text PDFArticle Synopsis
- This study investigated if colchicine, an anti-inflammatory medication, could reduce heart damage and remodeling after a ST-segment-elevation myocardial infarction (a type of heart attack) by comparing it to a placebo in a double-blind trial.
- The trial included 192 patients, with no significant differences in heart damage or remodeling observed between the colchicine and placebo groups at both 5 days and 3 months post-treatment.
- However, patients taking colchicine experienced higher rates of gastrointestinal side effects compared to those on the placebo, suggesting a potential drawback of the treatment.
Article Synopsis
- Inflammatory processes significantly worsen myocardial damage during ischemia-reperfusion injury in STEMI, leading to serious complications like heart failure and poor recovery.
- Colchicine, known for its strong anti-inflammatory effects, has shown a promising 50% reduction in infarct size in a phase II trial, compared to placebo, for acute STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
- The ongoing COVERT-MI trial aims to confirm these findings by comparing a short course of colchicine treatment to placebo in STEMI patients, measuring infarct size and other cardiac health indicators over 5 days.
A new institutional clinical trial assessed the improvement of sleep disorders in 40 children with autism treated by immediate-release melatonin formulation in different regimens (0.5 mg, 2 mg, and 6 mg daily) for one month. The objectives of present study were to (i) prepare low-dose melatonin hard capsules for pediatric use controlled by two complementary methods and (ii) carry out a stability study in order to determine a use-by-date.
View Article and Find Full Text PDF